Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
"Antimyeloangiogenic" therapy for cancer by inhibiting PlGF Loges S; Schmidt T; Carmeliet PClin Cancer Res 2009[Jun]; 15 (11): 3648-53Inhibition of tumor angiogenesis emerged as valuable strategy to treat cancer and has revolutionized the face of clinical oncology by prolonging the life of numerous cancer patients. However, the duration of this response is rather short and tumors rapidly evade treatment, leaving antiangiogenic treatment thus far unable to cure cancer. Hence, novel targets are needed to diversify antiangiogenic treatments and to overcome resistance. Recent data support the concept that tumor infiltration by bone marrow-derived myeloid cells confers resistance to current antiangiogenic drugs targeting primarily vascular endothelial growth factor (VEGF). In this review, we will summarize (pre)clinical data on the role of PlGF and its receptor VEGFR-1 in promoting angiogenesis and inflammation, and the "antimyeloangiogenic" activity of an antibody against PlGF (alphaPlGF), which may help to overcome resistance against VEGF(R)Is. Because of these promising results, a humanized alphaPlGF antibody (TB403) is currently evaluated in different phase I clinical trials in cancer patients.|Angiogenesis Inhibitors/*pharmacology[MESH]|Animals[MESH]|Antibodies/immunology/*pharmacology[MESH]|Humans[MESH]|Models, Biological[MESH]|Myeloid Cells/*drug effects/metabolism[MESH]|Placenta Growth Factor[MESH]|Pregnancy Proteins/*antagonists & inhibitors/immunology/metabolism[MESH]|Signal Transduction/drug effects[MESH]|Vascular Endothelial Growth Factor A/metabolism[MESH]|Vascular Endothelial Growth Factor Receptor-1/metabolism[MESH] |
